Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "Meta"

755 News Found

Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer
Clinical Trials | April 03, 2026

Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer

The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)


Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells
Medical Device | April 03, 2026

Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells

The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells


BioE3 policy accelerates India’s biomanufacturing ambitions with biofoundries, AI hubs & space biotech
Policy | April 03, 2026

BioE3 policy accelerates India’s biomanufacturing ambitions with biofoundries, AI hubs & space biotech

Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors


Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution
News | April 02, 2026

Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution

This marks a meaningful step in the company's continued expansion in the region


Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease
Clinical Trials | April 01, 2026

Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume


ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
Drug Approval | March 31, 2026

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial


Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy
News | March 31, 2026

Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy

Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively


Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
News | March 30, 2026

Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes

The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology


India gets first real-time GLP-1 therapy monitoring platform
Medical Device | March 27, 2026

India gets first real-time GLP-1 therapy monitoring platform

As Tracky launches integrated health solution


Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India
News | March 26, 2026

Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India

They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.